AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39630588 — intervention group
Group type: COMPARATOR
Intervention: Comparator foot (Össur Pro-Flex XC)
Number of subjects: 20
Study 39630633 — intervention group
Group type: EXPERIMENTAL
Intervention: HCS intervention communities
Number of subjects: 67
Study 39630633 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control communities
Number of subjects: 67
Study 39630656 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAN Discussion Aid
Number of subjects: 1733
Study 39630656 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1733
Study 39630680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%)
Number of subjects: 173
Study 39630680 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 173
Study 39630726 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (diaphragmatic and pursed lip breathing), practiced once a day, 3 days a week for 4 weeks.
Number of subjects: 54
Study 39630726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 54
Study 39630812 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing
Number of subjects: 210
Study 39630812 — intervention group
Group type: COMPARATOR
Intervention: Audiobook club (control)
Number of subjects: 210
Study 39630823 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM2 intervention
Number of subjects: 350
Study 39630823 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 39630935 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC + 3TC + AZT
Number of subjects: 13
Study 39630935 — intervention group
Group type: COMPARATOR
Intervention: ABC
Number of subjects: 13
Study 39630935 — intervention group
Group type: COMPARATOR
Intervention: 3TC
Number of subjects: 13
Study 39631042 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg twice daily
Number of subjects: 318
Study 39631042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 39631193 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors
Number of subjects: 642
Study 39631193 — intervention group
Group type: COMPARATOR
Intervention: Non-survivors
Number of subjects: 642
Study 39631193 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 642
Study 39631193 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving patients
Number of subjects: 642
Study 39631193 — intervention group
Group type: COMPARATOR
Intervention: Relatives of surviving patients
Number of subjects: 642
Study 39631193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 642
Study 39631208 — intervention group
Group type: COMPARATOR
Intervention: A-HCLF diet (higher-carbohydrate lower-fat diet with refined carbohydrate sources)
Number of subjects: 193
Study 39631208 — intervention group
Group type: COMPARATOR
Intervention: C-HCLF diet (higher-carbohydrate lower-fat diet with minimally refined carbohydrate sources)
Number of subjects: 193
Study 39631208 — intervention group
Group type: COMPARATOR
Intervention: LCHF diet (low-carbohydrate high-fat diet)
Number of subjects: 193
Study 39631208 — intervention group
Group type: COMPARATOR
Intervention: LCHF diet
Number of subjects: 193
Study 39631531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiology care
Number of subjects: 52011
Study 39631531 — intervention group
Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 52011
Study 39631531 — intervention group
Group type: COMPARATOR
Intervention: Other specialties (internist/neurologist/geriatrician)
Number of subjects: 52011
Study 39631536 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECaP intervention
Number of subjects: 0
Study 39631536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39631702 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (100 mg) with daily intermittent theta-burst stimulation (iTBS)
Number of subjects: 50
Study 39631702 — intervention group
Group type: COMPARATOR
Intervention: Placebo with daily intermittent theta-burst stimulation (iTBS)
Number of subjects: 50
Study 39631846 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (D+T)
Number of subjects: 161
Study 39631846 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 161
Study 39632005 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905
Study 39632005 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study 39632005 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge major bleeding
Number of subjects: 1905
Study 39632005 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (MB) after both procedures
Number of subjects: 1905
Study 39632107 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with cadonilimab (SOX regimen with cadonilimab)
Number of subjects: 37
Study 39632119 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D genetic risk estimates and lifestyle advice
Number of subjects: 355
Study 39632119 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D genetic risk estimates, lifestyle advice, and Fitbit's step goal setting and prompt functions
Number of subjects: 355
Study 39632119 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fitbit device only)
Number of subjects: 355
Study 39632119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 355
Study 39632125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 3328
Study 39632125 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 3328
Study 39632341 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Number of subjects: 61
Study 39632341 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Number of subjects: 61
Study 39632341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 39632499 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 140
Study 39632499 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MVPA
Number of subjects: 140
Study 39632722 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching algorithm using imaging and clinical variables
Number of subjects: 0
Study 39632722 — intervention group
Group type: COMPARATOR
Intervention: Manual screening by clinicians
Number of subjects: 0
Study 39633037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe asthma (CASI ≥ 4)
Number of subjects: 425
Study 39633037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild asthma (CASI < 4)
Number of subjects: 425
Study 39633037 — intervention group
Group type: COMPARATOR
Intervention: No asthma
Number of subjects: 425
Study 39633105 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text messaging program prompting weekly BP checks for 6 months.
Number of subjects: 300
Study 39633105 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 300
Study 39633105 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text messaging program.
Number of subjects: 300
Study 39633112 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 60 mg/day starting 5 days before surgery
Number of subjects: 34
Study 39633112 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment starting 5 days before surgery
Number of subjects: 34
Study 39633218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) 15 IU/kg
Number of subjects: 99
Study 39633218 — intervention group
Group type: COMPARATOR
Intervention: Plasma 10-15 ml/kg
Number of subjects: 99
Study 39633218 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 99
Study 39633218 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 99
Study 39633261 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent program (strength and balance training, bladder training with urge suppression strategies, home hazard assessment)
Number of subjects: 314
Study 39633261 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet on falls prevention and behavioral treatment for urinary incontinence (control group)
Number of subjects: 314
Study 39633319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 85
Study 39633319 — intervention group
Group type: COMPARATOR
Intervention: Therapist adherence (assessed by patients, therapists, and observers)
Number of subjects: 85
Study 39633319 — intervention group
Group type: COMPARATOR
Intervention: Therapist competence (assessed using the Cognitive Therapy Scale-Revised)
Number of subjects: 85
Study 39633321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber dietary intervention (HFDI) with a target fiber of 50 g/day from whole foods
Number of subjects: 45
Study 39633321 — intervention group
Group type: COMPARATOR
Intervention: Healthy control diet with a target fiber of 20 g/day
Number of subjects: 45
Study 39633321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber dietary intervention (HFDI)
Number of subjects: 45
Study 39633321 — intervention group
Group type: COMPARATOR
Intervention: Healthy control diet
Number of subjects: 45
Study 39633367 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled anticipatory guidance and peer support through four rounds of online parent empowerment sessions.
Number of subjects: 0
Study 39633367 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education materials (Control group).
Number of subjects: 0
Study 39633405 — intervention group
Group type: EXPERIMENTAL
Intervention: manual-based videoconferencing cognitive behavioral therapy (vCBT)
Number of subjects: 20
Study 39633425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stent omission
Number of subjects: 0
Study 39633425 — intervention group
Group type: COMPARATOR
Intervention: Ureteral stent placement
Number of subjects: 0
Study 39633425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts (stent omission and placement)
Number of subjects: 0
Study 39633425 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients and urologists
Number of subjects: 0
Study 39633467 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 20
Study 39633467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 39633570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2g administered within 45 minutes of symptom onset
Number of subjects: 3400
Study 39633570 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 3400
Study 39633573 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose Heparin
Number of subjects: 0
Study 39633573 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39634173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GX)
Number of subjects: 187
Study 39634173 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 187
Study 39634198 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 132
Study 39634261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0
Study 39634261 — intervention group
Group type: COMPARATOR
Intervention: Asciminib
Number of subjects: 0
Study 39634773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency continuous waveform group
Number of subjects: 120
Study 39634773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent waveform group
Number of subjects: 120
Study 39634788 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol Isotope Dilution (RID)
Number of subjects: 0
Study 39634788 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based modeling
Number of subjects: 0
Study 39635024 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplantation (FMT), five 100 ml doses prepared from 30 g stool from an unrelated healthy donor, administered daily to the upper gastrointestinal tract.
Number of subjects: 44
Study 39635024 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard of care (CS).
Number of subjects: 44
Study 39635465 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily for 12 weeks
Number of subjects: 57
Study 39635465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 39635498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising into pain
Number of subjects: 43
Study 39635498 — intervention group
Group type: COMPARATOR
Intervention: Exercising without pain
Number of subjects: 43
Study 39636024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin
Number of subjects: 0
Study 39636024 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study 39636092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction exercise (LL-BFRE)
Number of subjects: 21
Study 39636092 — intervention group
Group type: COMPARATOR
Intervention: Sham BFRE
Number of subjects: 21
Study 39636343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 370
Study 39636343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 39636384 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound (SR-US) imaging after bolus injection of microbubbles at clinical concentration
Number of subjects: 47
Study 39636384 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound (SR-US) imaging
Number of subjects: 47
Study 39636391 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 0
Study 39636391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39636496 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose education and direct provision of naloxone to incarcerated individuals upon release
Number of subjects: 3
Study 39636496 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating medications for opioid use disorder (MOUD) prior to release
Number of subjects: 3
Study 39636496 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to ongoing MOUD treatment in the community
Number of subjects: 3
Study 39636496 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support-facilitated treatment retention efforts
Number of subjects: 3
Study 39636496 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency housing in the immediate post-incarceration period
Number of subjects: 3
Study 39636502 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, tablet-based patient video education intervention focused on cancer care coordination
Number of subjects: 19
Study 39636623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of conventional type 1 dendritic cells (cDC1), 6 times weekly, followed by paclitaxel (80 mg/m2, intravenously, 12 times weekly), trastuzumab (8 mg/kg loading dose, then 6 mg/kg), and pertuzumab (840 mg loading dose, then 420 mg) every 3 weeks for 6 cycles starting from day 1 of cDC1 injections.
Number of subjects: 12
Study 39636623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of conventional type 1 dendritic cells (cDC1)
Number of subjects: 12
Study 39636638 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin, 25 mg
Number of subjects: 30
Study 39636638 — intervention group
Group type: COMPARATOR
Intervention: Niacin, 100 mg
Number of subjects: 30
Study 39636667 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) training for ACLS
Number of subjects: 102
Study 39636667 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based instruction (Control)
Number of subjects: 102
Study 39636667 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) training for ACLS (subgroup analysis)
Number of subjects: 102
Study 39636672 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother Tanzania (ECEM-TZ) - standardized text messages from birth to 6 weeks postpartum
Number of subjects: 124
Study 39636672 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study 39636679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral screen training for 12 weeks
Number of subjects: 24
Study 39636679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral screen training)
Number of subjects: 24
Study 39636682 — intervention group
Group type: EXPERIMENTAL
Intervention: Current medical decision-making participation self-efficacy
Number of subjects: 0
Study 39636875 — intervention group
Group type: EXPERIMENTAL
Intervention: GHK intervention (multi-component and multi-setting intervention)
Number of subjects: 1600
Study 39636875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1600
Study 39637186 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (4 mA for 20 minutes)
Number of subjects: 45
Study 39637186 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study 39637186 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 45
Study 39637307 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus hypomethylating agents
Number of subjects: 209
Study 39637726 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (≤5 mg/kg/day, ≤200 mg/day)
Number of subjects: 185
Study 39637726 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 185
Study 39637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 144
Study 39637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet discharge instructions
Number of subjects: 144
Study 39637747 — intervention group
Group type: COMPARATOR
Intervention: Verbal discharge instructions
Number of subjects: 144
Study 39637767 — intervention group
Group type: COMPARATOR
Intervention: BI 409306
Number of subjects: 235
Study 39637767 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model (14-day monitoring)
Number of subjects: 235
Study 39637767 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model (Trial-End timepoint)
Number of subjects: 235
Study 39637878 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAPS early childhood care and education programme
Number of subjects: 3858
Study 39637878 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3858
Study 39637881 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 1372
Study 39637881 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 1372
Study 39637881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372
Study 39637900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Number of subjects: 127
Study 39637900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant
Number of subjects: 127
Study 39637944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D) as neoadjuvant treatment
Number of subjects: 35
Study 39637944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D) as definitive treatment
Number of subjects: 35
Study 39637944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D)
Number of subjects: 35
Study 39638148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-citrulline supplementation
Number of subjects: 115
Study 39638148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 39638222 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately fit individuals (above average peak oxygen uptake)
Number of subjects: 1565
Study 39638222 — intervention group
Group type: COMPARATOR
Intervention: Unfit individuals (below average peak oxygen uptake)
Number of subjects: 1565
Study 39638275 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT) plus anticoagulation
Number of subjects: 500
Study 39638275 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone (No-CDT group)
Number of subjects: 500
Study 39638292 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-prepared platelet-rich fibrin (T-PRF)
Number of subjects: 10
Study 39638292 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 10
Study 39638429 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions and improved access to inpatient care
Number of subjects: 106259
Study 39638429 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual CVD incidence
Number of subjects: 106259
Study 39638429 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-standardised and sex-standardised CVD incidence rate
Number of subjects: 106259
Study 39638429 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD mortality
Number of subjects: 106259
Study 39638553 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd)
Number of subjects: 50
Study 39638564 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological-based intervention (3 sessions)
Number of subjects: 46
Study 39638585 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION (Acceptance and Commitment Therapy Intervention when Opioids are Necessary)
Number of subjects: 40
Study 39638585 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 40
Study 39638587 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary infection diagnosis by physicians
Number of subjects: 954
Study 39638596 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical treatment followed by application of autologous bioartificial palate mucosa
Number of subjects: 15
Study 39638596 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment (control group)
Number of subjects: 15